Biogen Backs Out Of Hemophilia, But Who Benefits?

With no buyers in the hemophilia space and a need to create a more streamlined company, Biogen Inc. announced May 3 that it has done the only thing it can – spin out its hemophilia business. It's still unclear whether this will be a positive strategy for either company.

Biogen CEO George Scangos said in a conference call accompanying the announcement that the time was right to spin off the hemophilia franchise, insisting the move will make both companies stronger. "The business has matured, it's profitable, it's growing, it can stand on its own, it has a pipeline," he claimed. It would have been "premature," he added, to make the move six or 12 months ago, which is why this outcome had not been considered any earlier.

Premature is likely an accurate description of the hemophilia business, even now. Eloctate and Alprolix, the hemophilia A and hemophilia...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip